Literature DB >> 19384547

Test-retest variability of quantitative [11C]PIB studies in Alzheimer's disease.

Nelleke Tolboom1, Maqsood Yaqub, Ronald Boellaard, Gert Luurtsema, Albert D Windhorst, Philip Scheltens, Adriaan A Lammertsma, Bart N M van Berckel.   

Abstract

PURPOSE: The aim of this study was to assess the test-retest variability of [11C]PIB studies in patients with Alzheimer's disease (AD) and healthy controls using several tracer kinetic models and to assess the suitability of the cerebellum as reference tissue.
METHODS: [11C]PIB studies with arterial sampling were performed in eight AD patients and eight healthy controls. Retest scans were performed in six controls and six AD patients. Data were analysed using plasma input and reference tissue models, together with simple ratios.
RESULTS: Test-retest variability was best ( approximately 3%) for SRTM2, a parametric method based on the simplified reference tissue model. Highest values ( approximately 10%) were found for plasma input models. Cerebellar V(T) values did not differ significantly between AD and controls.
CONCLUSION: Parametric SRTM2 with the cerebellum as reference tissue is the method of choice for quantitative analysis of [11C]PIB PET studies.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19384547      PMCID: PMC2758198          DOI: 10.1007/s00259-009-1129-6

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  29 in total

1.  Effects of statistical noise on graphic analysis of PET neuroreceptor studies.

Authors:  M Slifstein; M Laruelle
Journal:  J Nucl Med       Date:  2000-12       Impact factor: 10.057

Review 2.  Positron emission tomography compartmental models.

Authors:  R N Gunn; S R Gunn; V J Cunningham
Journal:  J Cereb Blood Flow Metab       Date:  2001-06       Impact factor: 6.200

3.  Noise reduction in the simplified reference tissue model for neuroreceptor functional imaging.

Authors:  Yanjun Wu; Richard E Carson
Journal:  J Cereb Blood Flow Metab       Date:  2002-12       Impact factor: 6.200

4.  Diffuse senile plaques occur commonly in the cerebellum in Alzheimer's disease.

Authors:  C L Joachim; J H Morris; D J Selkoe
Journal:  Am J Pathol       Date:  1989-08       Impact factor: 4.307

5.  Diffuse type of senile plaques in the cerebellum of Alzheimer-type dementia demonstrated by beta protein immunostain.

Authors:  H Yamaguchi; S Hirai; M Morimatsu; M Shoji; Y Nakazato
Journal:  Acta Neuropathol       Date:  1989       Impact factor: 17.088

6.  Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease.

Authors:  G McKhann; D Drachman; M Folstein; R Katzman; D Price; E M Stadlan
Journal:  Neurology       Date:  1984-07       Impact factor: 9.910

7.  Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer disease: a pilot phase 2 clinical trial.

Authors:  Craig W Ritchie; Ashley I Bush; Andrew Mackinnon; Steve Macfarlane; Maree Mastwyk; Lachlan MacGregor; Lyn Kiers; Robert Cherny; Qiao-Xin Li; Amanda Tammer; Darryl Carrington; Christine Mavros; Irene Volitakis; Michel Xilinas; David Ames; Stephen Davis; Konrad Beyreuther; Rudolph E Tanzi; Colin L Masters
Journal:  Arch Neurol       Date:  2003-12

Review 8.  Current progress in beta-amyloid immunotherapy.

Authors:  Dale Schenk; Michael Hagen; Peter Seubert
Journal:  Curr Opin Immunol       Date:  2004-10       Impact factor: 7.486

Review 9.  Neuropathological stageing of Alzheimer-related changes.

Authors:  H Braak; E Braak
Journal:  Acta Neuropathol       Date:  1991       Impact factor: 17.088

10.  Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B.

Authors:  William E Klunk; Henry Engler; Agneta Nordberg; Yanming Wang; Gunnar Blomqvist; Daniel P Holt; Mats Bergström; Irina Savitcheva; Guo-feng Huang; Sergio Estrada; Birgitta Ausén; Manik L Debnath; Julien Barletta; Julie C Price; Johan Sandell; Brian J Lopresti; Anders Wall; Pernilla Koivisto; Gunnar Antoni; Chester A Mathis; Bengt Långström
Journal:  Ann Neurol       Date:  2004-03       Impact factor: 10.422

View more
  30 in total

Review 1.  Amyloid imaging as a biomarker for cerebral β-amyloidosis and risk prediction for Alzheimer dementia.

Authors:  William E Klunk
Journal:  Neurobiol Aging       Date:  2011-12       Impact factor: 4.673

2.  Relative 11C-PiB Delivery as a Proxy of Relative CBF: Quantitative Evaluation Using Single-Session 15O-Water and 11C-PiB PET.

Authors:  Yin J Chen; Bedda L Rosario; Wenzhu Mowrey; Charles M Laymon; Xueling Lu; Oscar L Lopez; William E Klunk; Brian J Lopresti; Chester A Mathis; Julie C Price
Journal:  J Nucl Med       Date:  2015-06-04       Impact factor: 10.057

3.  Amyloid and its association with default network integrity in Alzheimer's disease.

Authors:  Sofie M Adriaanse; Ernesto J Sanz-Arigita; Maja A A Binnewijzend; Rik Ossenkoppele; Nelleke Tolboom; Daniëlle M E van Assema; Alle Meije Wink; Ronald Boellaard; Maqsood Yaqub; Albert D Windhorst; Wiesje M van der Flier; Philip Scheltens; Adriaan A Lammertsma; Serge A R B Rombouts; Frederik Barkhof; Bart N M van Berckel
Journal:  Hum Brain Mapp       Date:  2012-12-14       Impact factor: 5.038

4.  Appropriate use criteria for amyloid PET imaging cannot replace guidelines: on behalf of the European Association of Nuclear Medicine.

Authors:  Jan Booij; Javier Arbizu; Jacques Darcourt; Swen Hesse; Flavio Nobili; Pierre Payoux; Sabina Pappatà; Klaus Tatsch; Zuzana Walker; Marco Pagani
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-07       Impact factor: 9.236

5.  Progression of cerebral amyloid load is associated with the apolipoprotein E ε4 genotype in Alzheimer's disease.

Authors:  Timo Grimmer; Susanne Tholen; Behrooz H Yousefi; Panagiotis Alexopoulos; Annette Förschler; Hans Förstl; Gjermund Henriksen; William E Klunk; Chester A Mathis; Robert Perneczky; Christian Sorg; Alexander Kurz; Alexander Drzezga
Journal:  Biol Psychiatry       Date:  2010-07-02       Impact factor: 13.382

6.  Evaluation of 18F-RO-948 PET for Quantitative Assessment of Tau Accumulation in the Human Brain.

Authors:  Hiroto Kuwabara; Robert A Comley; Edilio Borroni; Michael Honer; Kelly Kitmiller; Joshua Roberts; Lorena Gapasin; Anil Mathur; Gregory Klein; Dean F Wong
Journal:  J Nucl Med       Date:  2018-08-10       Impact factor: 10.057

7.  Measurement of longitudinal β-amyloid change with 18F-florbetapir PET and standardized uptake value ratios.

Authors:  Susan M Landau; Allison Fero; Suzanne L Baker; Robert Koeppe; Mark Mintun; Kewei Chen; Eric M Reiman; William J Jagust
Journal:  J Nucl Med       Date:  2015-03-05       Impact factor: 10.057

Review 8.  Small-molecule PET Tracers for Imaging Proteinopathies.

Authors:  Chester A Mathis; Brian J Lopresti; Milos D Ikonomovic; William E Klunk
Journal:  Semin Nucl Med       Date:  2017-07-13       Impact factor: 4.446

Review 9.  Beta-amyloid deposition and the aging brain.

Authors:  Karen M Rodrigue; Kristen M Kennedy; Denise C Park
Journal:  Neuropsychol Rev       Date:  2009-11-12       Impact factor: 7.444

10.  In vivo validation of reconstruction-based resolution recovery for human brain studies.

Authors:  Jurgen E M Mourik; Mark Lubberink; Floris H P van Velden; Reina W Kloet; Bart N M van Berckel; Adriaan A Lammertsma; Ronald Boellaard
Journal:  J Cereb Blood Flow Metab       Date:  2009-10-21       Impact factor: 6.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.